RGNX Stock Overview
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$26.50|
|52 Week High||US$46.46|
|52 Week Low||US$18.69|
|1 Month Change||31.32%|
|3 Month Change||-17.52%|
|1 Year Change||-34.54%|
|3 Year Change||-48.41%|
|5 Year Change||34.18%|
|Change since IPO||-12.97%|
Recent News & Updates
The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business
The subdued stock price reaction suggests that REGENXBIO Inc.'s ( NASDAQ:RGNX ) strong earnings didn't offer any...
|RGNX||US Biotechs||US Market|
Return vs Industry: RGNX underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: RGNX underperformed the US Market which returned -18.5% over the past year.
|RGNX Average Weekly Movement||10.5%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: RGNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: RGNX's weekly volatility (10%) has been stable over the past year.
About the Company
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.
REGENXBIO Fundamentals Summary
|RGNX fundamental statistics|
Is RGNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RGNX income statement (TTM)|
|Cost of Revenue||US$234.94m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.35|
|Net Profit Margin||21.38%|
How did RGNX perform over the long term?See historical performance and comparison
Is RGNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RGNX?
Other financial metrics that can be useful for relative valuation.
|What is RGNX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does RGNX's PE Ratio compare to its peers?
|RGNX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: RGNX is good value based on its Price-To-Earnings Ratio (11.3x) compared to the peer average (37.1x).
Price to Earnings Ratio vs Industry
How does RGNX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Earnings vs Industry: RGNX is good value based on its Price-To-Earnings Ratio (11.3x) compared to the US Biotechs industry average (15.4x)
Price to Earnings Ratio vs Fair Ratio
What is RGNX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||11.3x|
|Fair PE Ratio||18x|
Price-To-Earnings vs Fair Ratio: RGNX is good value based on its Price-To-Earnings Ratio (11.3x) compared to the estimated Fair Price-To-Earnings Ratio (18x).
Share Price vs Fair Value
What is the Fair Price of RGNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RGNX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RGNX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: RGNX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Discover undervalued companies
How is REGENXBIO forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RGNX's earnings are forecast to decline over the next 3 years (-10.7% per year).
Earnings vs Market: RGNX's earnings are forecast to decline over the next 3 years (-10.7% per year).
High Growth Earnings: RGNX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: RGNX's revenue (12.4% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: RGNX's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RGNX's Return on Equity is forecast to be low in 3 years time (0.8%).
Discover growth companies
How has REGENXBIO performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RGNX has high quality earnings.
Growing Profit Margin: RGNX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RGNX has become profitable over the past 5 years, growing earnings by -8.6% per year.
Accelerating Growth: RGNX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RGNX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: RGNX's Return on Equity (14.7%) is considered low.
Discover strong past performing companies
How is REGENXBIO's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: RGNX's short term assets ($446.9M) exceed its short term liabilities ($119.9M).
Long Term Liabilities: RGNX's short term assets ($446.9M) exceed its long term liabilities ($215.8M).
Debt to Equity History and Analysis
Debt Level: RGNX is debt free.
Reducing Debt: RGNX has not had any debt for past 5 years.
Debt Coverage: RGNX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RGNX has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is REGENXBIO current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RGNX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ken Mills (46 yo)
Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills was with FOXKISER LLP, most recently as a Partner, from January 200...
CEO Compensation Analysis
Compensation vs Market: Ken's total compensation ($USD8.62M) is above average for companies of similar size in the US market ($USD4.05M).
Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.
Experienced Management: RGNX's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: RGNX's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
REGENXBIO Inc.'s employee growth, exchange listings and data sources
- Name: REGENXBIO Inc.
- Ticker: RGNX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.143b
- Shares outstanding: 43.13m
- Website: https://www.regenxbio.com
Number of Employees
- REGENXBIO Inc.
- 9804 Medical Center Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.